11月10日-13日，2023年美国心脏协会科学年会（2023 AHA）将在费城以线下+线上结合的方式召开。日前，大会日程已经公布，会议期间共设置8个最新科学研究专场（Late-Breaking Science，LBS）和7个特色科学研究专场（Featured Science，FS）。在今年的大会上，哪些重磅研究结果即将揭晓呢？

（注：本文中时间为美国东部时间）

最新科学研究（Late-Breaking Science，LBS）

LBS.01：肥胖——新疗法及其对人群健康的影响

日期：11月11日（周六）

时间：8:30 - 9:15am

★Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

SELECT试验：在超重或肥胖且无糖尿病的患者中，司美格鲁肽对心血管结局的影响

★Population Health and Obesity: Achieving Equity and Feasibility

人群健康与肥胖：实现公平与可行性

LBS.02：冠心病/急性冠状动脉综合征治疗热点话题

日期：11月11日（周六）

时间：9:45 - 11:00am

★DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes

DAPA-MI试验：一项基于注册研究的随机试验，评估达格列净用于急性心肌梗死不伴糖尿病患者治疗

★Restrictive versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial

MINT试验：心肌梗死合并贫血患者使用限制性和自由性输血策略的比较

★Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomised, Placebo-Controlled Trial

ORBITA-2随机安慰剂对照试验：经皮冠状动脉介入治疗（PCI）用于稳定型心绞痛

LBS.03：心力衰竭——心室辅助装置（VADs）、儿童和治疗费用

日期：11月11日（周六）

时间：1:30 - 2:45pm

★Avoidance of Aspirin With Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Clinical Trial

ARIES HM3国际双盲安慰剂对照试验初步结果：使用左心室辅助装置的晚期心力衰竭患者避免服用阿司匹林

★The TEAMMATE Trial: Everolimus to Prevent Rejection in Children After Cardiac Transplantation

TEAMMATE试验：依维莫司预防心脏移植后儿童排异反应

★Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters

将成本纳入射血分数降低的心力衰竭（HFrEF）共同决策中：心衰药物自付费用的试验

LBS.04：药物、饮食和产后管理优化高血压预后

日期：11月11日（周六）

时间：3:15 - 4:30pm

★Effectiveness of Blood Pressure-Lowering Intervention on Risk of Total Dementia Among Patients With Hypertension: A Cluster-Randomized Effectiveness Trial

CRHCP试验：一项集群随机有效性试验，评估在高血压患者中降压干预对痴呆风险的影响

★Long-Term Blood Pressure Control After Physician Optimised Postpartum Blood Pressure Self-Management: The POP-HT Randomised Clinical Trial

POP-HT随机临床试验：医生优化产后血压自我管理之后的长期血压控制

★Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial

CARDIA-SSBP随机交叉试验：评估膳食钠对中年人收缩压的影响

★Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension

KARDIA-1试验主要结果：一项在高血压患者中进行的2期研究，RNA干扰治疗药物Zilebesiran持续降压

LBS.05：房颤管理中令人震惊的决定

日期：11月12日（周日）

时间：8:00 - 9:15am

★Efficacy and Safety of Dual Direct Current Cardioversion versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation

在房颤合并肥胖患者中，双直流电心脏复律与单直流电心脏转律作为初始治疗策略的有效性和安全性

★Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial

AZALEA-TIMI 71随机试验主要结果：Abelacimab（新型XI/XIa因子抑制剂）vs利伐沙班治疗房颤

★Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours. The NOAH-AFNET 6 Trial

NOAH-AFNET 6试验：心房高频率事件（AHRE）持续时间≥24小时的患者中，艾多沙班抗凝治疗的有效性和安全性

★Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation

ARTESIA试验：阿哌沙班预防亚临床房颤患者的卒中

LBS.06：降脂治疗的未来——新的机制和方法

日期：11月12日（周日）

时间：3:30 - 4:45pm

★Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial

1b期Heart-1试验中期结果：VERVE-101的安全性和药效学作用（VERVE-101是一种DNA碱基编辑药物，通过持久关闭PCSK9基因来降低LDL-C）

★Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)

一种靶向脂蛋白(a)的长时间小干扰RNA（siRNA）药物Lepodisiran的有效性和安全性

★Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

REMAIN-2：一项多中心、随机、双盲、安慰剂对照3期试验，Recaticimab作为附件疗法用于非家族性高胆固醇血症和混合性高脂血症患者

★Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

REPRIEVE随机试验（预防HIV血管事件）机制子研究：匹伐他汀对HIV患者CAD和炎症生物标志物的影响

LBS.07：从地方到全球——实现预防公平

日期：11月13日（周一）

时间：8:00 - 9:15am

★Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events

ESPIRIT试验：强化降压在降低心血管事件风险方面的作用

★Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial

IMPACTS试验：一项集群随机试验，评估多方位实施策略对低收入患者血压控制效果的影响

★A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients

一项集群随机试验，评估高危患者自动转至集中药房服务以启动基于循证的他汀类药物治疗

★Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

HTN项目：尼日利亚高血压治疗Ⅱ型混合效果-实施中断时间系列研究的早期结果

LBS.08：床边的人工智能

日期：11月13日（周一）

时间：9:45 - 11:00am

★Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial

SPEC-AI随机临床试验：人工智能（AI）增强型数字听诊器筛查围产期心肌病

★Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

在门诊心衰患者中，验证语音分析应用程序检测心力衰竭恶化事件

★Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electrocardiogram (ARISE): A Pragmatic Randomized Controlled Trial

ARISE试验：一项实用随机对照试验，评估AI实现心电图快速识别ST段抬高型心肌梗死（STEMI）

★Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study

ORFAN研究：新型AI技术改善冠状动脉CT血管造影（CCTA）对非阻塞性CAD患者的风险分层

特色科学研究Featured Science（FS）

FS.01：电生理（EP）管理的创新

日期：11月11日（周六）

时间：9:45 - 11:00am

★Multi-National Survey on the Safety of the Post-Approval Clinical Use of Pulsed Field Ablation in 10,000+ Patients (MANIFEST-10K)

MANIFEST-10K：一项多国调查，在10,000+名患者中评估脉冲场消融获批上市后临床使用的安全性

★Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (Phase 2, ReVeRA-201)

2期ReVeRA-201随机对照研究：在症状性房颤患者中，评估Etripamil鼻喷雾剂紧急降低快速心室率的有效性和安全性

★Arrhythmic Risk in Biventricular Pacing Compared to Left Bundle Branch Area Pacing: Results From International Collaborative LBBAP Study (I-CLAS)

国际合作LBBAP研究（I-CLAS）结果：双心室起搏与左束支区域起搏的心律失常风险比较

FS.02：冠状动脉血运重建——从有影响力的临床试验中吸取经验教训

日期：11月11日（周六）

时间：1:30 - 2:45pm

★Left Anterior Descending Non-culprit Lesion Location And Clinical Outcomes In Patients With St-segment Elevation Myocardial Infarction And Multivessel Disease: Results From The Complete Trial

Complete试验结果：在STEMI合并多血管病变患者中，左前降支非罪犯病变的位置与临床结局

★Resource Use and Cost Comparisons of a Novel Precision Medicine Evaluation Strategy for Suspected Coronary Artery Disease versus Usual Testing: Results From the PRECISE Randomized Trial

PRECISE随机试验结果：在疑似冠状动脉疾病患者中，一种新的精确医学评估策略与常规检测的资源使用和成本比较

★PCI or CABG versus Medical Therapy in the ISCHEMIA Trial: A Post Hoc Analysis

ISCHEMIA事后分析：PCI/CABG与药物治疗的比较

★Impact of Cardiac Arrest Before Randomization on the Efficacy of ECLS in Patients With Infarct-Related Cardiogenic Shock. A Sub-Analysis of the Prospective EClS-Shock Trial

前瞻性EClS-Shock试验亚组分析：在梗死相关心源性休克患者中，随机分组前心脏骤停对ECLS治疗效果的影响

FS.03：首次用于人体的心血管疾病治疗新方法

日期：11月12日（周日）

时间：8:00 - 9:15am

★Phase I Result of a Novel Antiplatelet Drug CG-0255 That is Fast-Acting, Long Lasting and Available for Either IV or Oral Administration

新型抗血小板药物CG-0255的I期研究结果，该药物作用快速、持久，可静脉或口服

★Safety and Blood Pressure Lowering Effects of a Novel and Long-Acting Natriuretic Peptide Receptor 1 Agonist in Healthy Participants: A First-in-Human Clinical Study

新型长效利钠肽受体1激动剂在健康参与者中的安全性和降压作用：首次人类临床研究

★Safety And Efficacy Of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium As Biological Ventricular Assist Tissue In Terminal Heart Failure - BioVAT-HF-DZHK20

BioVAT-HF-DZHK20：在终末期心衰中，诱导多能干细胞衍生的工程化人心肌作为生物心室辅助组织的安全性和有效性

★Phase 1 Gene Therapy Trial In Patients With Advanced Heart Failure Using A Novel Cardiotropic AAV Vector Targeting Protein Phosphatase Inhibitor-1

1期基因治疗试验：在晚期心力衰竭患者中，使用一种新型嗜心性AAV载体靶向蛋白磷酸酶抑制剂-1

FS.04：HFpEF和ATTR‐CM治疗

日期：11月12日（周日）

时间：9:45 - 11:00am

★Effects Of Semaglutide On Symptoms, Function And Quality Of Life In Patients With The Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The Step-hfpef Trial

STEP-HFpEF试验：司美格鲁肽对肥胖型射血分数保留的心衰（HFpEF）患者症状、功能和生活质量的影响

★Sodium-Glucose Cotransporter-2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

SGLT2抑制剂在转甲状腺素蛋白淀粉样变心肌病（ATTR‐CM）中的作用

★Acoramidis Improves Clinical Outcomes In Transthyretin Amyloid Cardiomyopathy Patients

Acoramidis改善转甲状腺素蛋白淀粉样变心肌病患者的临床结局

FS.05：心肌梗死治疗新方法，能否带来新希望？

日期：11月13日（周一）

时间：8:00 - 9:15am

★Half-dose Tenecteplase Or Primary PCI In Older Patients With St-elevation Myocardial Infarction: The STREAM-2 1-year Mortality Follow-up Results

STREAM-2试验1年死亡率随访结果：老年STEMI患者半剂量替奈普酶vs直接PCI治疗

★Pre-Hospital Rule-Out of Non-ST-Segment Elevation Acute Coronary Syndrome by a Single Troponin Measurement: Final One-Year Outcomes of the ARTICA Randomised Trial

ARTICA随机试验1年最终结果：通过单次肌钙蛋白检测院前排除非ST段抬高型急性冠状动脉综合征（NST-ACS）

★Association of Use and Dose of Lipid Lowering Therapy Post Acute Myocardial Infarction in the Elderly With 5-year Survival: The French Registry on ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

FAST-MI（法国STEMI和NSTEMI登记研究）：老年人急性心肌梗死后降脂治疗及其剂量与5年生存率的关系

★Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction (STEMI)

RPH-104对STEMI患者白细胞介素1的阻断作用

★Prehospital High-Dose Glucocorticoid Treatment for Post-Cardiac Arrest Syndrome Following Resuscitated Out-of-Hospital Cardiac Arrest: The STEROHCA Trial

STEROHCA试验：院前大剂量糖皮质激素治疗院外心脏骤停复苏后心脏骤停综合征

FS.06：生命与运动——运动员、心律失常和心力衰竭治疗方法

日期：11月13日（周一）

时间：9:45 - 11:15am

★Incidence and Causes of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-year Study

一项为期20年的研究：全国大学生体育协会运动员心源性猝死的发生率及原因分析

★Vigorous Exercise in Individuals With Long QT Syndrome (LQTS): Primary Results of the Prospective, Multinational Lifestyle and Exercise in LQTS (LIVE-LQTS) Study

LIVE-LQTS国际多中心研究主要结果：剧烈运动对长QT综合征（LQTS）患者的影响

★Safety And Efficacy Of The Jewel, A Novel Patch Wearable Cardioverter Defibrillator: Results From The Jewel Investigational Device Exemption Study

JEWEL试验器械豁免研究结果：新型贴片可穿戴式心脏复律除颤器JEWEL的安全性和有效性

★Effect of a Walking Intervention on Functional Capacity in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial

WATCHFUL试验：在HFrEF患者中，步行干预对功能能力的影响

★The Liraglutide Effect On Atrial Fibrillation (LEAF) Study

LEAF研究：利拉鲁肽对房颤的影响

FS.07：从动脉到静脉的奇妙之旅

日期：11月13日（周一）

时间：1:30 - 2:45pm

★A Multicenter, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial

KABUKI试验：一项多中心随机对照试验，评估艾多沙班vs华法林治疗慢性血栓性栓塞性肺动脉高压

★Ultrasound-assisted Catheter-directed Thrombolysis Versus Surgical Pulmonary Embolectomy For Intermediate-high Or High-risk Pulmonary Embolism: A Randomized Phase II Non-inferiority Study

一项2期随机非劣效性研究，超声辅助经导管接触性溶栓（CDT）vs外科肺动脉切开取栓术（SPE）治疗中高风险或高风险肺栓塞

★Nicotinamide Riboside to Improve Walking Performance in Peripheral Artery Disease: A Randomized Clinical Trial

烟酰胺核苷（NR）改善外周动脉疾病患者行走能力的随机临床试验

★Pemafibrate Reduces Incidence of Lower Extremity Ischemic Ulcer and Gangrene: Evidence From PROMINENT

来自PROMINENT的证据：Pemafibrate降低下肢缺血性溃疡和坏疽的发病率

信源：AHA官网